A Study of PF-08052667 in People With Bladder Cancer

Full Title

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of PF-08052667 as a Single Agent and in Combination Therapy in Participants 18 Years of Age and Older With Bladder Cancer

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Eugene Pietzak’s office at 646-422-4781.

Protocol
26-256
Phase
Phase I (phase 1)
Investigator
Eugene Pietzak
Co-Investigators
Alvin C. Goh
Diseases
Genitourinary Cancer › Bladder Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07206225
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description